Laekna Inc
Laekna Inc is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biotech products.
Business. Laekna Inc (2105.HK) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Laekna Inc (2105.HK) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
Laekna Inc's capital structure is characterized by a low debt-to-equity ratio of 0.1, indicating a conservative approach to financing. However, the company's liquidity position is rated as medium, with a current ratio of 5.54, suggesting it has sufficient short-term assets to cover its liabilities, but with a negative net cash position after subtracting total debt.
Profitability metrics for Laekna Inc are negative, with a return on equity of -0.1943 and a return on assets of -0.1621. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit, which is below the typical performance expected in the biotechnology and medical research industry.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if its primary market or product line experiences a downturn.
Laekna Inc's growth trajectory is currently negative, with a net loss of 229,318,000 CNY and a free cash flow of -224,929,000 CNY. The company's operating cash flow is also negative at -92,822,000 CNY, indicating that it is not generating enough cash from its operations to sustain its activities without external financing.
The risk assessment for Laekna Inc highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential challenges in maintaining liquidity without additional financing. The dilution risk is low, indicating that the company is not expected to issue a significant number of new shares in the near term.
Recent events and filings for Laekna Inc include analyst estimates that suggest a mean price target of 24.89 CNY and a median price target of 24.16 CNY. The mean recommendation from analysts is 1.50, indicating a generally positive outlook, with two strong-buy and two buy recommendations, and no hold recommendations.
- Laekna Inc has a conservative capital structure with a low debt-to-equity ratio, but faces medium liquidity risk.
- The company is currently unprofitable, with negative returns on equity and assets.
- Revenue and geographic diversification are limited, increasing exposure to market-specific risks.
- Analysts have a generally positive outlook, with a mean price target of 24.89 CNY and no hold recommendations.
- "margin_outlook_rationale": "The company's negative operating and net income suggest deteriorating margins, driven by high R&D and operational costs.",
- "rd_outlook_rationale": "High R&D expenses are expected to continue as the company invests in biotechnology development.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,07 |
| Revenue | —no estimate | —no estimate | 284,2M CNY |
| Operating income | —no estimate | —no estimate | -54,2M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Laekna Inc Market data — financials · 2026-05-26
- Laekna Inc Market data — analyst estimates · 2026-05-26